entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 00:52:42 - browse：6

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Senate panel eyes new effort on drug shortages

Wikipedia

WSS

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Bristol 'take

At least 12 people were injured in a blast at a port in northwest Turkey

Democratic lawmaker calls for 'well

The UK government moves asylum

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

explore

entertainment

explore

Heart attack and stroke risk calculators need revising

Why workplace violence is so common in health care

Heart attack and stroke risk calculators need revising

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Psychedelics group wrestles with new pharma identity

Senate panel eyes new effort on drug shortages

Heart attack and stroke risk calculators need revising

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Drug repurposing or repositioning? The language matters

The UK government moves asylum

focus

When women are denied an abortion, their children fare worse than peers

FDA authorizes Novavax’s updated Covid

The UK government moves asylum

'The Exorcist' director William Friedkin dead at 87

Bristol 'take

Sana to lay off nearly a third of staff, de

Wikipedia

Wikipedia

focus

explore